✦ LIBER ✦

P-513 Improving pulmonary function in patients with malignant pleural mesothelioma: Results of the phase III trial of pemetrexed + cisplatin vs. cisplatin

✍ Scribed by Pistolesi, M.; Symanowski, J.; Gatzemeier, U.; Emri, S.; Conte, P.; Manegold, C.; Levitan, N.; Blatter, J.; Paoletti, P.

Book ID: 118572209
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 193 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)92480-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-435 Long-term survival update from the

P-435 Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs cisplatin in patients with malignant pleural mesothelioma (MPM)

✍ Vogelzang, N.; Symanowski, J.; Rusthoven, J.; Manegold, C.; Boyer, M.; Nguyen, B 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 323 KB

P-401 Evaluating improvement in patient-

P-401 Evaluating improvement in patient-reported dyspnea and pulmonary function tests (PFTs) in patients with malignant pleural mesothelioma (MPM): An analysis as part of the 448-patient randomized pemetrexed + cisplatin versus cisplatin trial

✍ Gralla, R.; Symanowski, J.; Boyer, M.; Paoletti, P.; Rusthoven, J.; Manegold, C. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 298 KB

905 Documenting symptom palliation with

905 Documenting symptom palliation with chemotherapy using the LCSS-Meso: Results from the randomized trial of pemetrexed plus cisplatin vs cisplatin alone in patients with malignant pleural mesothelloma

✍ R. Gralla; P. Hollen; A. Liepa; J. Symanowski; J. Rusthoven; M. Boyer; J. Jassem 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Cisplatin in combination with irinotecan

Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma : A pilot phase II clinical trial and pharmacokinetic profile

✍ Takashi Nakano; A. Philippe Chahinian; Miho Shinjo; Naoki Togawa; Atsushi Tonomu 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 2 views

The purpose of this study was to assess the efficacy and toxicity of a combination of cisplatin and irinotecan (CPT-11) in the treatment of patients with malignant pleural mesothelioma and to characterize the pharmacokinetic profiles of CPT-11 and its active metabolite, 7-ethyl-10-hydroxycamptotheci

P-431 Updated multiple regression analys

P-431 Updated multiple regression analysis of prognostic variables for survival in malignant pleural mesothelioma (MPM): Observations from a phase III study of pemetrexed plus cisplatin versus cisplatin and evolution of the regression model

✍ Symanowski, J.; Rusthoven, J.; Vogelzang, N. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 327 KB

VANTAGE 014: Vorinostat (V) in Patients

VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial

✍ L.M. Krug; H. Kindler; H. Calvert; C. Manegold; A.S. Tsao; D. Fennell; G.M. Lubi 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 64 KB